Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016; New Report Launched

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The report Cathepsin B – Pipeline Review, H1 2016, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by Companies in Phase I, Phase 0, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
• The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JDp

Related Reports;

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDG

Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDN

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDx